Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 7
1969 2
1970 7
1971 6
1972 14
1973 12
1974 5
1975 11
1976 15
1977 18
1978 14
1979 10
1980 16
1981 20
1982 17
1983 23
1984 27
1985 45
1986 42
1987 39
1988 67
1989 104
1990 164
1991 218
1992 238
1993 332
1994 298
1995 328
1996 295
1997 326
1998 433
1999 508
2000 532
2001 485
2002 396
2003 420
2004 455
2005 513
2006 466
2007 454
2008 503
2009 529
2010 465
2011 489
2012 486
2013 467
2014 442
2015 424
2016 370
2017 388
2018 345
2019 147
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

11,555 results
Results by year
Filters applied: . Clear all
Page 1
Discovery and development of varenicline for smoking cessation.
Jordan CJ, Xi ZX. Jordan CJ, et al. Expert Opin Drug Discov. 2018 Jul;13(7):671-683. doi: 10.1080/17460441.2018.1458090. Epub 2018 Mar 28. Expert Opin Drug Discov. 2018. PMID: 29587555 Free PMC article. Review.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788 Free article.
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T. Nishina T, et al. Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30. Invest New Drugs. 2018. PMID: 28965185 Clinical Trial.
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC. Tabernero J, et al. J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324363 Clinical Trial.
OTC brimonidine (Lumify) for ocular redness.
Med Lett Drugs Ther. 2018 Oct 22;60(1558):176. Med Lett Drugs Ther. 2018. PMID: 30335046 No abstract available.
Drugs for smoking cessation.
Med Lett Drugs Ther. 2019 Jul 15;61(1576):105-110. Med Lett Drugs Ther. 2019. PMID: 31381546 Review. No abstract available.
An insight into medicinal chemistry of anticancer quinoxalines.
Kaushal T, Srivastava G, Sharma A, Singh Negi A. Kaushal T, et al. Bioorg Med Chem. 2019 Jan 1;27(1):16-35. doi: 10.1016/j.bmc.2018.11.021. Epub 2018 Nov 15. Bioorg Med Chem. 2019. PMID: 30502116 Review.
Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.
Primas N, Suzanne P, Verhaeghe P, Hutter S, Kieffer C, Laget M, Cohen A, Broggi J, Lancelot JC, Lesnard A, Dallemagne P, Rathelot P, Rault S, Vanelle P, Azas N. Primas N, et al. Eur J Med Chem. 2014 Aug 18;83:26-35. doi: 10.1016/j.ejmech.2014.06.014. Epub 2014 Jun 10. Eur J Med Chem. 2014. PMID: 24946216
11,555 results
Jump to page
Feedback